Literature DB >> 25007963

Breast cancer and bone metastases: the association of axial skeleton MRI findings with skeletal-related events and survival.

Christian B van der Pol1, Mark E Schweitzer, Gina Di Primio, Marcos L Sampaio, Ania Kielar, Mark Clemons, Arash Jaberi.   

Abstract

The purpose of this study was to determine if bone metastasis characteristics on axial skeleton MRI are associated with either skeletal-related events (SREs) or survival in breast cancer patients. A retrospective review was performed on 247 breast cancer patients with bone metastases identified on axial skeleton MRI. MRI studies were reviewed for metastases T1 signal, signal uniformity, complete vertebral metastatic marrow replacement, metastases quantity, and distribution. Odds ratio (OR) and hazard ratios (HR) were calculated, with 95 % confidence intervals (95 % CI), to determine association with either future SREs or survival. At the time of analysis, 174 (70 %) patients had developed SREs and 176 (71 %) patients were dead. Features of skeletal metastases associated with SREs included the presence of complete metastatic marrow replacement within any vertebra; OR 2.363 (95 % CI 1.240-4.504, P = 0.0090), and more widely distributed metastases; OR 1.239 (95 % CI 1.070-1.435, P = 0.0040). Features associated with shorter survival included the presence of complete metastatic marrow replacement within any vertebra; HR 1.500 (95 % CI 1.105-2.036, P = 0.0093), and more widely distributed metastases; HR 1.141 (95 % CI 1.047-1.243, P = 0.0027). Metastases T1 signal, signal uniformity, and surprisingly quantity were not associated with SREs or survival. Axial skeleton MRI was able to identify characteristics predictive of future SREs and survival. These characteristics could be used for risk stratification for future trials if prospectively validated.

Entities:  

Mesh:

Year:  2014        PMID: 25007963     DOI: 10.1007/s10549-014-3046-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  3 in total

1.  Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey.

Authors:  Mashari AlZahrani; Mark Clemons; Lisa Vandermeer; Marta Sienkiewicz; Arif Ali Awan; Brian Hutton; Gregory R Pond; Terry L Ng
Journal:  J Bone Oncol       Date:  2020-11-10       Impact factor: 4.072

2.  Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.

Authors:  Mashari Alzahrani; Carol Stober; Michelle Liu; Arif Awan; Terry L Ng; Gregory Pond; Bader Alshamsan; Lisa Vandermeer; Mark Clemons
Journal:  Support Care Cancer       Date:  2022-01-21       Impact factor: 3.603

Review 3.  Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: A systematic review of the real world data.

Authors:  Hongwei Zhang; Wei Zhu; Ewelina Biskup; Weige Yang; Ziang Yang; Hong Wang; Xiaochun Qiu; Chengjiao Zhang; Guangxia Hu; Guangfu Hu
Journal:  J Bone Oncol       Date:  2018-02-03       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.